Doetsch Grether has received valuation services
Located in the heart of Basel, Switzerland, Doetsch Grether AG is a medium-sized, family-owned company with traditional values that specializes in the marketing and distribution of products in the pharma, OTC and consumer care segments.
Doetsch Grether’s portfolio consists of its own brands, such as the famous Grether’s Pastilles®, neo-angin® and Sulgan®N, as well as distribution brands that include Magnesium-Diasporal®, Tiger Balm® and Pearl Drops®, which are successfully sold throughout Switzerland.
Oaklins’ team in Switzerland has repeatedly advised Doetsch Grether on valuation topics, contract drafting and the preparation of second opinions in connection with various acquisition projects.
Lukas Grimm
CFO, Doetsch Grether AG
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more